Biomarkers and the diagnosis of preclinical dementia

Alzheimer's disease pathology accumulates years before the onset of clinical symptoms and has been termed ‘preclinical dementia’. Biomarkers have been developed to detect this pathology – namely, brain amyloid deposition and markers of neurodegeneration. In this article we describe these biomar...

Full description

Saved in:
Bibliographic Details
Published in:BJPsych advances 2018-11, Vol.24 (6), p.422-430
Main Authors: Lilford, Philippa, Hughes, Julian C.
Format: Article
Language:English
Subjects:
Activities of daily living
Alzheimer's disease
Biomarkers
Cognitive ability
Dementia
Medical imaging
Memory
Neurodegeneration
Pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c2518-4518a80da406b1e94ba44068b5ee8df67b0736a7189a23fcb920dfa1cdf998e13
cites cdi_FETCH-LOGICAL-c2518-4518a80da406b1e94ba44068b5ee8df67b0736a7189a23fcb920dfa1cdf998e13
container_end_page 430
container_issue 6
container_start_page 422
container_title BJPsych advances
container_volume 24
creator Lilford, Philippa
Hughes, Julian C.
description Alzheimer's disease pathology accumulates years before the onset of clinical symptoms and has been termed ‘preclinical dementia’. Biomarkers have been developed to detect this pathology – namely, brain amyloid deposition and markers of neurodegeneration. In this article we describe these biomarkers and review the evidence for their clinical use in predicting risk both in the cognitively ‘normal’ and in those who already have established cognitive decline. We also discuss the limitations and ethical considerations of these tests and consider whether we should start incorporating Alzheimer's disease biomarkers into clinical practice. We find that, because many cognitively healthy people will have Alzheimer's pathology, and it is not clear whether this does help predict future risk of Alzheimer's disease, diagnosing preclinical dementia carries numerous ethical implications and is currently not being advocated outside research settings.
doi_str_mv 10.1192/bja.2018.28
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2206475966</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cupid>10_1192_bja_2018_28</cupid><sourcerecordid>2206475966</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2518-4518a80da406b1e94ba44068b5ee8df67b0736a7189a23fcb920dfa1cdf998e13</originalsourceid><addsrcrecordid>eNptkLFOwzAQhi0EElXpxAtEYkQJtuM49ggVFKRKLDBb5_hcXNqk2OnA2-OqFSwsd__w6T_dR8g1oxVjmt_ZNVScMlVxdUYmnDayFFLJ89_cqksyS2lNaaY4awWdEPEQhi3ET4ypgN4V4wcWLsCqH1JIxeCLXcRuE_rQwaZwuMV-DHBFLjxsEs5Oe0renx7f5s_l8nXxMr9flh1vmCpFHqCoA0GlZaiFBZGjsg2icl62lra1hJYpDbz2ndWcOg-sc15rhayekptj7y4OX3tMo1kP-9jnk4ZzKkXbaCkzdXukujikFNGbXQz5p2_DqDmYMdmMOZgxXGW6PNGwtTG4Ff6V_sf_ACMpY8A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2206475966</pqid></control><display><type>article</type><title>Biomarkers and the diagnosis of preclinical dementia</title><source>Cambridge Journals Online</source><creator>Lilford, Philippa ; Hughes, Julian C.</creator><creatorcontrib>Lilford, Philippa ; Hughes, Julian C.</creatorcontrib><description>Alzheimer's disease pathology accumulates years before the onset of clinical symptoms and has been termed ‘preclinical dementia’. Biomarkers have been developed to detect this pathology – namely, brain amyloid deposition and markers of neurodegeneration. In this article we describe these biomarkers and review the evidence for their clinical use in predicting risk both in the cognitively ‘normal’ and in those who already have established cognitive decline. We also discuss the limitations and ethical considerations of these tests and consider whether we should start incorporating Alzheimer's disease biomarkers into clinical practice. We find that, because many cognitively healthy people will have Alzheimer's pathology, and it is not clear whether this does help predict future risk of Alzheimer's disease, diagnosing preclinical dementia carries numerous ethical implications and is currently not being advocated outside research settings.</description><identifier>ISSN: 2056-4678</identifier><identifier>EISSN: 2056-4686</identifier><identifier>DOI: 10.1192/bja.2018.28</identifier><language>eng</language><publisher>Cambridge, UK: Cambridge University Press</publisher><subject>Activities of daily living ; Alzheimer's disease ; Biomarkers ; Cognitive ability ; Dementia ; Medical imaging ; Memory ; Neurodegeneration ; Pathology</subject><ispartof>BJPsych advances, 2018-11, Vol.24 (6), p.422-430</ispartof><rights>Copyright © The Royal College of Psychiatrists 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2518-4518a80da406b1e94ba44068b5ee8df67b0736a7189a23fcb920dfa1cdf998e13</citedby><cites>FETCH-LOGICAL-c2518-4518a80da406b1e94ba44068b5ee8df67b0736a7189a23fcb920dfa1cdf998e13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.cambridge.org/core/product/identifier/S2056467818000282/type/journal_article$$EHTML$$P50$$Gcambridge$$H</linktohtml><link.rule.ids>314,780,784,27922,27923,72730</link.rule.ids></links><search><creatorcontrib>Lilford, Philippa</creatorcontrib><creatorcontrib>Hughes, Julian C.</creatorcontrib><title>Biomarkers and the diagnosis of preclinical dementia</title><title>BJPsych advances</title><addtitle>BJPsych advances</addtitle><description>Alzheimer's disease pathology accumulates years before the onset of clinical symptoms and has been termed ‘preclinical dementia’. Biomarkers have been developed to detect this pathology – namely, brain amyloid deposition and markers of neurodegeneration. In this article we describe these biomarkers and review the evidence for their clinical use in predicting risk both in the cognitively ‘normal’ and in those who already have established cognitive decline. We also discuss the limitations and ethical considerations of these tests and consider whether we should start incorporating Alzheimer's disease biomarkers into clinical practice. We find that, because many cognitively healthy people will have Alzheimer's pathology, and it is not clear whether this does help predict future risk of Alzheimer's disease, diagnosing preclinical dementia carries numerous ethical implications and is currently not being advocated outside research settings.</description><subject>Activities of daily living</subject><subject>Alzheimer's disease</subject><subject>Biomarkers</subject><subject>Cognitive ability</subject><subject>Dementia</subject><subject>Medical imaging</subject><subject>Memory</subject><subject>Neurodegeneration</subject><subject>Pathology</subject><issn>2056-4678</issn><issn>2056-4686</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNptkLFOwzAQhi0EElXpxAtEYkQJtuM49ggVFKRKLDBb5_hcXNqk2OnA2-OqFSwsd__w6T_dR8g1oxVjmt_ZNVScMlVxdUYmnDayFFLJ89_cqksyS2lNaaY4awWdEPEQhi3ET4ypgN4V4wcWLsCqH1JIxeCLXcRuE_rQwaZwuMV-DHBFLjxsEs5Oe0renx7f5s_l8nXxMr9flh1vmCpFHqCoA0GlZaiFBZGjsg2icl62lra1hJYpDbz2ndWcOg-sc15rhayekptj7y4OX3tMo1kP-9jnk4ZzKkXbaCkzdXukujikFNGbXQz5p2_DqDmYMdmMOZgxXGW6PNGwtTG4Ff6V_sf_ACMpY8A</recordid><startdate>201811</startdate><enddate>201811</enddate><creator>Lilford, Philippa</creator><creator>Hughes, Julian C.</creator><general>Cambridge University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>M2M</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>201811</creationdate><title>Biomarkers and the diagnosis of preclinical dementia</title><author>Lilford, Philippa ; Hughes, Julian C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2518-4518a80da406b1e94ba44068b5ee8df67b0736a7189a23fcb920dfa1cdf998e13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Activities of daily living</topic><topic>Alzheimer's disease</topic><topic>Biomarkers</topic><topic>Cognitive ability</topic><topic>Dementia</topic><topic>Medical imaging</topic><topic>Memory</topic><topic>Neurodegeneration</topic><topic>Pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lilford, Philippa</creatorcontrib><creatorcontrib>Hughes, Julian C.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Psychology Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>BJPsych advances</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lilford, Philippa</au><au>Hughes, Julian C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biomarkers and the diagnosis of preclinical dementia</atitle><jtitle>BJPsych advances</jtitle><addtitle>BJPsych advances</addtitle><date>2018-11</date><risdate>2018</risdate><volume>24</volume><issue>6</issue><spage>422</spage><epage>430</epage><pages>422-430</pages><issn>2056-4678</issn><eissn>2056-4686</eissn><abstract>Alzheimer's disease pathology accumulates years before the onset of clinical symptoms and has been termed ‘preclinical dementia’. Biomarkers have been developed to detect this pathology – namely, brain amyloid deposition and markers of neurodegeneration. In this article we describe these biomarkers and review the evidence for their clinical use in predicting risk both in the cognitively ‘normal’ and in those who already have established cognitive decline. We also discuss the limitations and ethical considerations of these tests and consider whether we should start incorporating Alzheimer's disease biomarkers into clinical practice. We find that, because many cognitively healthy people will have Alzheimer's pathology, and it is not clear whether this does help predict future risk of Alzheimer's disease, diagnosing preclinical dementia carries numerous ethical implications and is currently not being advocated outside research settings.</abstract><cop>Cambridge, UK</cop><pub>Cambridge University Press</pub><doi>10.1192/bja.2018.28</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2056-4678
ispartof BJPsych advances, 2018-11, Vol.24 (6), p.422-430
issn 2056-4678
2056-4686
language eng
recordid cdi_proquest_journals_2206475966
source Cambridge Journals Online
subjects Activities of daily living
Alzheimer's disease
Biomarkers
Cognitive ability
Dementia
Medical imaging
Memory
Neurodegeneration
Pathology
title Biomarkers and the diagnosis of preclinical dementia
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T13%3A07%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biomarkers%20and%20the%20diagnosis%20of%20preclinical%20dementia&rft.jtitle=BJPsych%20advances&rft.au=Lilford,%20Philippa&rft.date=2018-11&rft.volume=24&rft.issue=6&rft.spage=422&rft.epage=430&rft.pages=422-430&rft.issn=2056-4678&rft.eissn=2056-4686&rft_id=info:doi/10.1192/bja.2018.28&rft_dat=%3Cproquest_cross%3E2206475966%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2518-4518a80da406b1e94ba44068b5ee8df67b0736a7189a23fcb920dfa1cdf998e13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2206475966&rft_id=info:pmid/&rft_cupid=10_1192_bja_2018_28&rfr_iscdi=true